Patents by Inventor Paul A. Moore

Paul A. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210292407
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: January 19, 2021
    Publication date: September 23, 2021
    Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
  • Patent number: 11126698
    Abstract: A distributed ledger system includes a device registry and a software registry. The device registry includes a plurality of device identifiers. Each device identifier uniquely identifies a device that has been registered with the distributed ledger system. The software registry includes a plurality of software license identifiers. Each software license identifier uniquely identifies a software license that has been registered with the distributed ledger system. The distributed ledger system also includes transaction management components that are configured to record device transaction information associated with the plurality of devices and software transaction information associated with the plurality of software licenses. The distributed ledger system also includes access control components that are configured to enforce access control policies related to the plurality of devices and the plurality of software licenses.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: September 21, 2021
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Sonal Gaurav Vaish, Timothy Paul Baumann, Seema Lal Gulabrani, Brittany Jon Moore
  • Publication number: 20210276032
    Abstract: An irrigation stand assembly for hands free irrigation includes a handle has a first portion slidably engaging a second portion such that the handle has a telescopically adjustable length. A spray nozzle is coupled to the handle and the spray nozzle has an input and an output. The input is fluidly attachable to a fluid source to receive a fluid and the output sprays the fluid for irrigation. A stand is vertically orientable on a support surface and the stand releasably engages the handle for retaining the handle in an upright position. In this way the spray nozzle can be positioned on the support surface to irrigate the support surface without requiring the user to bend over.
    Type: Application
    Filed: March 3, 2020
    Publication date: September 9, 2021
    Inventor: Paul Moore
  • Patent number: 11098119
    Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”).
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 24, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Scott Koenig
  • Patent number: 11097647
    Abstract: A cargo body wall including an interior side defining an interior plane for facing a cargo receiving volume, and an exterior side. A primary logistics track is elongated in a first direction and situated in the cargo body wall, and a secondary logistics track is elongated in a second direction intersecting the first direction. The primary logistics track includes first and second inward expansions projecting inward of the interior plane, each of the first and second inward expansions having at least one opening therein providing access to a logistics fitting accommodation area within the cargo body wall. The secondary logistics track is arranged to cross the primary logistics track at a position between the first and second inward expansions.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: August 24, 2021
    Assignee: STI Holdings, Inc.
    Inventor: Steven Paul Moore
  • Publication number: 20210237638
    Abstract: A cargo body wall including an interior side defining an interior plane for facing a cargo receiving volume, and an exterior side. A primary logistics track is elongated in a first direction and situated in the cargo body wall, and a secondary logistics track is elongated in a second direction intersecting the first direction. The primary logistics track includes first and second inward expansions projecting inward of the interior plane, each of the first and second inward expansions having at least one opening therein providing access to a logistics fitting accommodation area within the cargo body wall. The secondary logistics track is arranged to cross the primary logistics track at a position between the first and second inward expansions.
    Type: Application
    Filed: January 31, 2020
    Publication date: August 5, 2021
    Inventor: Steven Paul Moore
  • Patent number: 11072653
    Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: July 27, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210206851
    Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 8, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210155694
    Abstract: The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRHI Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL I Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain. The invention particularly concerns to such DA×CD3 Binding Molecules comprising a vCD3-Binding Domain which exhibit reduced affinity for CD3 and are capable of mediating redirected killing of target cells expressing a DA and exhibit lower levels of cytokine release relative to a DA×CD3 Binding Molecule comprising a rCD3-Binding Domain.
    Type: Application
    Filed: February 13, 2019
    Publication date: May 27, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Ling Huang, Chia-Ying Kao Lam, Gurunadh Reddy Chichili, Ralph Froman Alderson, Paul A. Moore, Leslie S. Johnson
  • Publication number: 20210130470
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Inventors: Leslie S. JOHNSON, Gurunadh Reddy CHICHILI, Kalpana SHAH, Ross LA MOTTE-MOHS, Paul A. Moore, Ezio Bonvini, Scott KOENIG
  • Patent number: 10954301
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: March 23, 2021
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210047426
    Abstract: The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Application
    Filed: August 24, 2020
    Publication date: February 18, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Publication number: 20210029090
    Abstract: A system and method for providing secure access to an organization's internal directory service from external hosted services. The system includes a remote directory service configured to accept directory service queries from an application running on hosted services. The remote directory service passes the queries to a directory service proxy server inside a firewall of the organization via a secure connection service. The directory service proxy server passes the queries to the internal directory service inside said firewall. Request responses from the internal directory service pass through the directory service proxy server to the remote directory service through said firewall via the secure connection service. The remote directory service returns the response to the requesting application.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 28, 2021
    Inventors: Paul MOORE, Nathaniel Wayne YOCOM
  • Patent number: 10858430
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 8, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Publication number: 20200377612
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Application
    Filed: May 7, 2020
    Publication date: December 3, 2020
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Patent number: 10834133
    Abstract: A technique to enforce mobile device security policy is based on a “risk profile” of the individual device, where the risk profile is fine-grained and based on the types of applications installed on the device, the services they are accessing, and the operation(s) the user granted the device authorization to perform. Thus, the approach takes into account not only the actual applications installed on the device (and those actively in use), but also the services those applications are accessing, and the scope of operations the user has granted the device authorization to perform. By combining this information to create the risk profile, a suitable security policy, including one that does not unnecessarily degrade device usability, may then be applied.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: November 10, 2020
    Assignee: International Business Machines Corporation
    Inventors: Simon Gilbert Canning, David Paul Moore, Shane Bradley Weeden, Stephen Viselli
  • Patent number: 10798057
    Abstract: A system and method for providing secure access to an organization's internal directory service from external hosted services. The system includes a remote directory service configured to accept directory service queries from an application running on hosted services. The remote directory service passes the queries to a directory service proxy server inside a firewall of the organization via a secure rendezvous service. The directory service proxy server passes the queries to the internal directory service inside said firewall. Request responses from the internal directory service pass through the directory service proxy server to the remote directory service through said firewall via the secure rendezvous service. The remote directory servicer returns the response to the requesting application.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: October 6, 2020
    Assignee: CENTRIFY CORPORATION
    Inventors: Paul Moore, Nathaniel Wayne Yocom
  • Patent number: 10787521
    Abstract: The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 29, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Publication number: 20200291129
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: January 21, 2020
    Publication date: September 17, 2020
    Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
  • Patent number: D929270
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: August 31, 2021
    Assignee: Toyota Motor North America, Inc.
    Inventors: Douglas A. Moore, Christopher Lee, Paul Ellsworth Nichols, Christina Danielle Tapp, Thomas Mitchell Dair